382P - The therapeutic changes influence on the treatment results of the hypopharyngeal cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Head and Neck Cancers
Presenter Keiko Yuasa-Nakagawa
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors K. Yuasa-Nakagawa1, R. Yoshimura2, K. Toda2, H. Shibuya3, M. Kojima2
  • 1Radiation Oncology, Tokyo Medical and Dental University, 113-8519 - Tokyo/JP
  • 2Radiation Oncology, Tokyo Medical and Dental University, 1138519 - Tokyo/JP
  • 3Radiology, Toshima Hospital, 1730015 - Tokyo/JP



As the technical development of radiation therapy has brought us more precise and efficient therapeutic approaches, the effects of the therapy has been ameliorated. Especially in the head and neck regions, sophisticated techniques make the dose distribution better and reduce the adverse events during and after the therapy. Until the middle of 2008, the 2 dimensional X-ray plan had been routinely used in our institution for the treatment of the head and neck cancers and the irradiation to the neck was mostly from two sides of the body. From 2009 almost all plans have been performed by the 3D-CT plan and oblique injections of the beams have become possible. Recently the intensity modulated radiation therapy (IMRT) has been started to use routinely. In case of the chemotherapy, three agents therapy with taxotere, cisplatin and 5-fluorouracil (TPF) has been started in 2007. In this report we evaluate the therapeutic results of the chemoradiation therapy for the hypopharyngeal cancer from the point of view of the changes of the therapeutic method.


From Jan. 2005 till Dec. 2014, we have treated 116 hypopharyngeal cancer patients by radiation therapy. Over 90 patients had the advanced diseases of the stage IV. Their ages were between 42 and 86. Only 6 were female. We reviewed the medical records of these patients retrospectively and obtained the patients characteristics and the therapeutic methods and results. The survival rates were calculated using the Kaplan–Meier product limit method.


In case of 2D plan, the 5 year overall survival rate was only 40% in contrast to the rate using 3D-CT plan was about 70%. If the concurrent full dose of three courses of TPF and 3D-CT plan radiation therapy of 60Gy have been completed, the 5 year disease-specific survival (DSS) and disease-free survival (DFS) rates were about 90% and 70%, respectively.


The use of 3D-CT plan and concurrent chemotherapy using TPF was the most important therapeutic condition for hypopharyngeal cancers. We could obtain the reasonable result of 5 year DDS rate of 90% even for advanced diseases. For the future, we hope that the results will be further improved by IMRT reducing the adverse events and newly developed molecular-targeted agents.

Clinical trial indentification

Legal entity responsible for the study



Tokyo Medical and Dental University


All authors have declared no conflicts of interest.